sildenafil

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
84
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Sexual Dysfunction

Conditions

Sexual Dysfunction, Depression

Trial Timeline

Jan 1, 2001 โ†’ Jun 1, 2005

About sildenafil

sildenafil is a approved stage product being developed by Pfizer for Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00375297. Target conditions include Sexual Dysfunction, Depression.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (14)

NCT IDPhaseStatus
NCT01897740Pre-clinicalCompleted
NCT01889966ApprovedCompleted
NCT01642407ApprovedCompleted
NCT01360671Phase 2Withdrawn
NCT01108900Pre-clinicalCompleted
NCT00800592Phase 1Completed
NCT00666198Pre-clinicalCompleted
NCT00768573Pre-clinicalCompleted
NCT00625079ApprovedWithdrawn
NCT00249730ApprovedCompleted
NCT00245596ApprovedCompleted
NCT00746967Phase 2Completed
NCT00145483ApprovedCompleted
NCT00375297ApprovedCompleted

Competing Products

18 competing products in Sexual Dysfunction

See all competitors
ProductCompanyStageHype Score
DapoxetineJohnson & JohnsonPhase 3
77
Gardasil VaccineMerckPre-clinical
23
sildenafilPfizerPhase 2
51
CP-866,087 + CP-866,087 + CP-866,087 + PlaceboPfizerPhase 2
51
PF-00446687 + PlaceboPfizerPhase 2
51
BremelanotidePfizerPhase 2
51
Sildenafil 100 mg + PlaceboPfizerPhase 2
51
AlfuzosinSanofiApproved
84
AVANAFIL + placeboSanofiPhase 3
76
Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved
82
Placebo + 0.5 mgTestosterone + 10 mg BuspironeBrain BiotechPhase 2
44
Placebo + Testosterone + Buspirone hydrochlorideBrain BiotechPhase 2
44
Placebo + Sildenafil + TestosteroneBrain BiotechPhase 2
44
tibolone + estradiol-norethisteroneOrganonPhase 3
72
Bremelanotide + PlaceboPalatin TechnologiesPhase 3
69
bremelanotidePalatin TechnologiesPhase 2
44
BremelanotidePalatin TechnologiesPhase 3
69
EVO100 + PlaceboEvofem BiosciencesPhase 3
69